Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HCW Biologics Inc.HCWB · Entity 8172 | VP of Development | May 31, 2022 | June 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HCW Biologics Inc.
Report date May 31, 2022 · Filed June 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,141 |
Ending reported balance
After 2022-05-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-31 · Exercise / conversion · Acquired 12,856 · Balance 43,427 Row 2 · 2022-05-31 · Exercise / conversion · Acquired 1,714 · Balance 45,141 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.14 · Expires 2029-05-29 | Direct | 18,001 |
Reported balance
After 2022-05-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-31 · Exercise / conversion · Disposed 12,856 · Balance 18,001 F1: These option shares were part of a stock option grant covering 51,428 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2030-12-22 | Direct | 6,857 |
Reported balance
After 2022-05-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-31 · Exercise / conversion · Disposed 1,714 · Balance 6,857 F2: 20% of the total shares subject to the stock option grant will vest on December 22, 2021; 20% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2023; and 35% of the total shares subject to the stock option grant will vest on December 22, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: These option shares were part of a stock option grant covering 51,428 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2023.
F2: 20% of the total shares subject to the stock option grant will vest on December 22, 2021; 20% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2023; and 35% of the total shares subject to the stock option grant will vest on December 22, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2022 Filed Jun 2, 2022 16:16 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,714 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001209191-22-033517 · doc4.xml · derivative · entry 4 Jiao Jin-an · CIK 0001866271 · VP of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,857 Underlying: Common Stock · 1,714 shares Expires 2030-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 20% of the total shares subject to the stock option grant will vest on December 22, 2021; 20% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2023; and 35% of the total shares subject to the stock option grant will vest on December 22, 2024. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 16:16 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,856 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-22-033517 · doc4.xml · derivative · entry 3 Jiao Jin-an · CIK 0001866271 · VP of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,001 Underlying: Common Stock · 12,856 shares Expires 2029-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These option shares were part of a stock option grant covering 51,428 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2023. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 16:16 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 1,714 | $0.21 | $359.94 |
DisclosureSEC source: 0001209191-22-033517 · doc4.xml · nonDerivative · entry 2 Jiao Jin-an · CIK 0001866271 · VP of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 16:16 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 12,856 | $0.14 | $1,799.84 |
DisclosureSEC source: 0001209191-22-033517 · doc4.xml · nonDerivative · entry 1 Jiao Jin-an · CIK 0001866271 · VP of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 12:31 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 10,000 | $2.42 | $24,150.00 |
DisclosureSEC source: 0001209191-21-068274 · doc4.xml · nonDerivative · entry 1 Jiao Jin-an · CIK 0001866271 · VP of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,571 F1 · price: The range of prices for the shares of Common Stock is from $2.40 to $2.43. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 17:45 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-055527 · doc4.xml · derivative · entry 1 Jiao Jin-an · CIK 0001866271 · VP of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-09-07 F1 · derivative.exercise_date: The option will vest as follows: 20% will vest on September 8, 2022, 20% will vest on September 8, 2023, 25% will vest on September 8, 2024 and 35% will vest on September 8, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.